Effect of liver failure on the pharmacokinetics of cyclophosphamide

Eur J Clin Pharmacol. 1984;26(5):591-3. doi: 10.1007/BF00543491.


The pharmacokinetics of cyclophosphamide was investigated in 7 patients in severe liver failure. The pharmacokinetic data were compared with those derived from a matched control group of patients with normal liver function. The half-life (t1/2) of cyclophosphamide following intravenous administration in patients with liver failure was 12.5 +/- 1.0 h (m +/- SD), which was significantly longer than in the normal controls in whom it was 7.6 +/- 1.4 h (p less than 0.001). The mean total body clearance (Clt) was significantly smaller in liver failure at 44.8 + 8.61 X kg-1 than in the controls in whom it was 63.0 +/- 7.61 X kg-1 (p less than 0.01). It is concluded that severe liver disease has a significant effect on the disposition of cyclophosphamide, and that it could lead to accumulation of the drug in the body.

MeSH terms

  • Adult
  • Aged
  • Cyclophosphamide / metabolism*
  • Female
  • Humans
  • Kinetics
  • Liver Diseases / metabolism*
  • Male
  • Middle Aged


  • Cyclophosphamide